Menu Search
Equities

SAGE Therapeutics Inc

SAGE:NMQ

SAGE Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.91
  • Today's Change0.06 / 1.24%
  • Shares traded47.59k
  • 1 Year change-74.73%
  • Beta0.8651
Data delayed at least 15 minutes, as of Nov 22 2024 14:42 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 20-Nov-24
Select bar for recommendation details.
Recommendations20-Nov-24
Buy0
Outperform2
Hold17
Sell1
Strong Sell0

Share price forecast in USD

The 17 analysts offering 12 month price targets for SAGE Therapeutics Inc have a median target of 9.00, with a high estimate of 26.00 and a low estimate of 4.00. The median estimate represents a 85.57% increase from the last price of 4.85.
High436.1%26.00
Med85.6%9.00
Low-17.5%4.00

Earnings history & estimates in USD

On Oct 29, 2024, SAGE Therapeutics Inc reported 3rd quarter 2024 losses of -1.53 per share. This result was in line with the consensus of the 19 analysts following the company and exceeded last year's 3rd quarter results by 54.60%.
The next earnings announcement is expected on Feb 12, 2025.
Average growth rate-32.01%
SAGE Therapeutics Inc reported annual 2023 losses of -9.05 per share on Feb 14, 2024.
Average growth rate-7.95%
More ▼

Revenue history & estimates in USD

Sage Therapeutics, Inc. had 3rd quarter 2024 revenues of 11.87m. This bettered the 10.80m consensus of the 19 analysts covering the company. This was 260.38% above the prior year's 3rd quarter results.
Average growth rate+681.92%
Sage Therapeutics, Inc. had revenues for the full year 2023 of 86.46m. This was 1,024.84% above the prior year's results.
Average growth rate+4,267.58%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.